Eisai receives positive opinion on epilepsy drug
Inovelon has been approved as an adjunctive therapy in Lennox-Gastaut Syndrome (LGS) from the Committee for Medicinal Products for Human Use, the scientific body of the European Medicines
BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their partnership to expand Brukinsa (zanubrutinib) access for chronic lymphocytic leukaemia (CLL) treatment in low- and middle-income countries until 2028.